Reported
Nanexa Shares Surge Over 150% After Licensing Deal With Novo Nordisk
The Swedish drug-delivery microcap's stock more than doubled following a licensing agreement with the maker of Wegovy.
· 1 min read
Pharmaceuticals
OfficialReported
Punjab University and Chinese partners launch two cooperation platforms
The University of the Punjab and Chinese institutions unveiled two new platforms aimed at deepening collaboration in pharmaceuticals and public welfare initiatives.
· 1 min read
Reported
Novo Nordisk's new strategy depends on rebuilding investor trust, CEO says
CEO Mike Doustdar says Novo Nordisk is ready to broaden its ambitions again, but investors remain unconvinced after a period of setbacks for the drugmaker.
· 1 min read
EGEGazette
Reported
Novo Nordisk shares fall as company outlines strategy beyond Wegovy
The Danish drugmaker is seeking to reassure investors it can compete in the increasingly crowded weight-loss drug market, CNBC reported.
· 1 min read
EGEGazette
Reported
Novo Nordisk shares drop as much as 7% despite $23 billion obesity drug sales target
The decline came even as the Danish drugmaker set an ambitious sales goal for its weight-loss treatments, CNBC reported.
· 1 min read
Reported
Berenberg Upgrades Eli Lilly Stock, Citing Room for Growth in GLP-1 Market
The investment bank raised its rating on the pharmaceutical company to "buy" from "hold," pointing to continued momentum in weight-loss and diabetes drugs.
· 1 min read
Reported
AstraZeneca's Tozorakimab Shows Positive Results in Two Late-Stage COPD Trials
Full data from late-stage studies reinforce hopes the drug could become a major treatment for chronic obstructive pulmonary disease, according to CNBC.
· 1 min read
Reported
Novartis Shares Fall 9% After Setbacks in Three Drug Trials
Shares of the Swiss pharmaceutical company dropped sharply on Tuesday after disappointing results from its del-desiran drug trial, according to a CNBC report.
· 1 min read
Reported
Novartis cholesterol drug setback raises stakes for Amgen, Eli Lilly
Novartis' failure in reducing Lp(a) levels intensifies competition among drugmakers racing to prove lower cholesterol correlates with fewer cardiovascular events.
· 1 min read